Wai Yuen Tong Medicine Holdings Limited provided earnings guidance for the financial year ended 31 March 2023. For the period, the company expected to record a loss attributable to owners of the parent of not more than HKD 35 million for the financial year ended 31 March 2023 as compared with a loss attributable to owners of the parent for the financial year ended 31 March 2022 of approximately HKD 108.9 million as published in the Company's 2022 annual report.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.224 HKD | +0.90% | -1.32% | -44.00% |
1st Jan change | Capi. | |
---|---|---|
-44.00% | 31.98M | |
+39.50% | 6.23B | |
+5.32% | 3.32B | |
-18.39% | 2.91B | |
-6.41% | 2.42B | |
+42.43% | 1.94B | |
-14.15% | 1.59B | |
-4.27% | 1.58B | |
+38.37% | 1.49B | |
-15.57% | 1.48B |
- Stock Market
- Equities
- 897 Stock
- News Wai Yuen Tong Medicine Holdings Limited
- Wai Yuen Tong Medicine Holdings Limited Provides Earnings Guidance for the Financial Year Ended 31 March 2023